Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study
Journal of the Saudi Heart Association · 20.02.2026 · 38 (1)
DOI: 10.37616/2212-5043.1478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 20.02.2026. Verfasst von Nazlı Dilek Çolak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy, Marmara University, Institute of Health Sciences, 34854, Istanbul, Turkey. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Carbohydrate antigen 125 (CA125) is associated with different cardiovascular conditions. This study aimed to determine CA125 levels in patients with acute coronary syndrome (ACS) and the potential relationship between major adverse cardiac events (MACE) in the short-term following.
Methods
This prospective cohort study was conducted in a coronary care unit between May and November 2022. Plasma CA125 levels were measured only once upon hospital admission. Patients were followed for six months. All-cause mortality, recurrent acute coronary syndrome, requirement for revascularization, decompensated heart failure, cardiogenic pulmonary edema, atrial fibrillation, and stroke were recorded as MACE.
Results
A total of 127 patients were included in this study. The mean left ventricular ejection fraction (LVEF) was 50.5%. The median plasma CA125 level was 14.6 KU/L. There was a, significant positive relationship between CA125 and high-sensitivity cardiac troponin (hs-cTn) (r = 0.315, p < 0.001) and pro–B-type natriuretic peptide (proBNP) (r = 0.423, p < 0.001), and a weak negative relationship with LVEF (r= −0.186, p = 0.037) value.
Conclusions
Plasma CA125 levels were correlated with the pro-BNP and hs-cTn, established ACS biomarkers. An additional notable finding was the weak correlation with LVEF. Elevated plasma CA125 levels might be used to identify patients with ACS who are at higher risk of MACE at six months.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacy, Marmara University, Institute of Health Sciences, 34854, Istanbul, Turkey.
- Cardiology, University of Health Sciences, Istanbul Teaching and Research Hospital, 34098, Istanbul, Turkey.
- Emergency Medicine, Istinye University, Hospital Medical Park Gaziosmanpasa, 34250, Istanbul, Turkey.
- Clinical Pharmacy, Marmara University, 34854, Istanbul, Turkey.
Zitieren
APA
Çolak, N. D., Karabağ, T., Çalışkan, O., & Tezcan, S. (2026). Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study. Journal of the Saudi Heart Association, 38(1). https://doi.org/10.37616/2212-5043.1478
Vancouver
Çolak ND, Karabağ T, Çalışkan O, Tezcan S. Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study. Journal of the Saudi Heart Association. 2026;38(1). doi:10.37616/2212-5043.1478
BibTeX
@article{olak2026,
author = {Çolak, Nazlı Dilek and Karabağ, Turgut and Çalışkan, Onuralp and Tezcan, Songül},
title = {Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study},
journal = {Journal of the Saudi Heart Association},
year = {2026},
volume = {38},
number = {1},
doi = {10.37616/2212-5043.1478}
}
EUVIMED